Bernstein Liebhard LLP Investigates Claims on Behalf of Holders of Pacira Pharmaceuticals Stock

April 16, 2015

Bernstein Liebhard LLP is investigating whether the Board of Directors of Pacira Pharmaceuticals (“Pacira” or the “Company”) (NASDAQ: PCRX) breached their fiduciary duties by allegedly failing to ensure compliance with U.S. Food and Drug Administration regulations.

Pacira is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients.  The Company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), a non-opioid local analgesic for postsurgical pain control, was commercially launched in the United States in April 2012.

Pacira announced today that it received a subpoena from the U.S. Department of Justice, U.S. Attorney’s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to EXPAREL.

Pacira stock plummeted from an April 15, 2015 closing price of $92.39 to open on April 16, 2015 at $84.26 – a drop of over 7% that caused a large loss in Pacira’s market capitalization.

If you currently hold Pacira shares and are interested in discussing your rights, and/or have information relating to the matter, please contact Joseph R. Seidman, Jr. at (877) 779-1414 or seidman@bernlieb.com.

Bernstein Liebhard LLP has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients.  The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs’ firms in the country.